权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Grading of Malignant Potential in Brain Tumors using Proton MR Spectroscopy

使用质子磁共振波谱对脑肿瘤的恶性潜能进行分级

基本信息

批准号：
10671294
负责人：
SHIINO Akihiko
金额：
$ 0.7万
依托单位：
SHIGA UNIVERSITY OF MEDICAL SCIENCE
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
1998
资助国家：
日本
起止时间：
1998 至 1999
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-10671294/
关键词：
MAGNETIC RESONANCE SPECTROSCOPY BRAIN TUMOR CREATE CHOLINE NECROSIS MALIGNANCY スペクトロスコピィー

项目摘要

Intracranial meningiomas are frequently occurring tumors that grow slowly and usually are amenable to surgical treatment. Nevertheless, 5 to 20% of meningiomas show atypical and 1.4 to 11.1% show malignant histologic features. These nonbenign meningiomas grow rapidly, invade adjacent brain, tend to recur, and sometimes result in a poor outcome despite aggressive treatment. Patients with an incidental finding of meningioma or imaging studies sometimes may be followed clinically without surgical intervention. However, some highly aggressive tumors will require surgical treatment, even if small and found in elderly patients. Reliable noninvasive preoperative evaluation of tumor grade is therefore a very important goal.Computed tomography (CT) and magnetic resonance imaging (MRI) are generally excellent studies for diagnosis of meningiomas. While these imaging modalities also contribute to assessment of malignancy or tumor grade, these studies have only limited ability to evaluate tumor growth rate. We believe that biochemical evaluation of meningiomas using magnetic resonance spectroscopy (MRS) offers a more accurate means of estimating growth rate. An immunohistologic method of identifying cell proliferation using MIB-1 antibody staining has proven very useful for evaluating proliferative and malignant potential in tumors specimens, and in the present study we used a MIB-1 staining index (MIB-1 SI) as a standard for evaluating preoperative MRS in determination of the characteristics of atypical meningiomas.

颅内脑膜瘤是一种常见的肿瘤，生长缓慢，通常适合手术治疗。然而，5 - 20%的脑膜瘤表现为非典型性，1.4 - 11.1%表现为恶性组织学特征。这些非良性脑膜瘤生长迅速，侵犯邻近脑，往往复发，有时即使积极治疗也会导致不良结局。偶尔发现脑膜瘤或影像学检查的患者有时可以在临床上随访，而无需手术干预。然而，一些高度侵袭性的肿瘤需要手术治疗，即使很小，并且在老年患者中发现。因此，可靠的无创性术前评估肿瘤分级是一个非常重要的目标。计算机断层扫描（CT）和磁共振成像（MRI）通常是诊断脑膜瘤的优秀研究。虽然这些成像方式也有助于评估恶性程度或肿瘤分级，但这些研究评估肿瘤生长速率的能力有限。我们相信，使用磁共振波谱（MRS）的脑膜瘤的生物化学评价提供了一个更准确的估计生长速度的方法。MIB-1抗体染色鉴定细胞增殖的免疫组织学方法已被证明对评估肿瘤标本的增殖和恶性潜能非常有用，在本研究中，我们使用MIB-1染色指数（MIB-1 SI）作为标准，用于评估术前MRS确定非典型脑膜瘤的特征。